Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.78 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.78 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.78 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.78 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.78 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.78 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.78 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.78 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.78 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.78 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.78 |
| ▸ | NPY5R | Q15761 | 6/20 | 0.69 |
| ▸ | MEN1 | O00255 | 3/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.65 |
| ▸ | ACACB | O00763 | 1/20 | 0.64 |
| ▸ | NPY1R | P25929 | 1/20 | 0.64 |
| ▸ | BCHE | P06276 | 2/20 | 0.61 |
| ▸ | MAOB | P27338 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8208140 | 1.00 | HDAC3 (0.78) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL7023898 | 0.89 | HDAC3 (0.77) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL4007525 | 0.88 | HDAC3 (0.71) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL4007519 | 0.88 | HDAC3 (0.71) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL7971370 | 0.85 | HDAC3 (0.74) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL5205575 | 0.85 | GBA1 (0.79) | NPY5RMEN1KMT2AALDH1A1CYP2C9 | |
| SCHEMBL3851236 | 0.85 | GBA1 (0.79) | NPY5RMEN1KMT2AALDH1A1CYP2C9 | |
| SCHEMBL7960267 | 0.84 | HDAC3 (0.73) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL29877086 | 0.84 | HDAC3 (0.73) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL4393015 | 0.83 | NPY5R (0.70) | HDAC3HDAC4HDAC1HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1257539-B1 | AMINO PYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF OBESITY AND OTHER DISORDERS | ORTHO MCNEIL PHARM INC (US) | 2004-12-29 | — | — | EP | disclosed |
| EP-1076644-B1 | N-SUBSTITUTED AMINOTETRALINS AS LIGANDS FOR THE NEUROPEPTIDE Y Y5 RECEPTOR USEFUL IN THE TREATMENT OF OBESITY AND OTHER DISORDERS | ORTHO MCNEIL PHARM INC (US) | 2004-06-23 | — | — | EP | disclosed |
| US-6531478-B2 | For therapy of eating disorder, obesity, bulimia nervosa, diabetes, binge eating, anorexia nervosa, dyslipidimia, hypertension, memory loss, epileptic seizures, migraine, sleep disturbances, pain, sexual/reproductive disorders | KORDIK CHERYL P (US) | 2003-03-11 | — | — | US | disclosed |
| US-20020065289-A1 | Amino pyrazole derivatives useful for the treatment of obesity and other disorders | KORDIK CHERYL P (US) | 2002-05-30 | — | — | US | disclosed |
| EP-1076644-A1 | N-SUBSTITUTED AMINOTETRALINS AS LIGANDS FOR THE NEUROPEPTIDE Y Y5 RECEPTOR USEFUL IN THE TREATMENT OF OBESITY AND OTHER DISORDERS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2001-02-21 | — | — | EP | disclosed |
| US-6140354-A | FOR TREATMENT OF DISORDERS OR DISEASE STATES CAUSED BY EATING DISORDERS, OBESITY, BULIMIA NERVOSA, DIABETES, HYPERTENSION, MEMORY LOSS, EPILEPTIC SEIZURES, MIGRAINE, SLEEP DISTURBANCES, PAIN, SEXUAL/REPRODUCTIVE DISORDERS, DEPRESSION | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2000-10-31 | — | — | US | disclosed |
| WO-1999055667-A1 | N-SUBSTITUTED AMINOTETRALINS AS LIGANDS FOR THE NEUROPEPTIDE Y Y5 RECEPTOR USEFUL IN THE TREATMENT OF OBESITY AND OTHER DISORDERS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 1999-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020065289-A1 | Amino pyrazole derivatives useful for the treatment of obesity and other disorders | NPY5R, NPY1R, NPY4R | HDAC3 2019/4885HDAC4 2927/4885HDAC1 2995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.